IPCALAB

Ipca Laboratories Share Price

 

 

Invest in Ipca Laboratories with 3.28X leverage

Invest with MTF

Performance

  • Low
  • ₹1,416
  • High
  • ₹1,431
  • 52 Week Low
  • ₹1,168
  • 52 Week High
  • ₹1,595
  • Open Price₹1,418
  • Previous Close₹1,417
  • Volume31,615
  • 50 DMA₹1,442.08
  • 100 DMA₹1,422.52
  • 200 DMA₹1,410.78

Investment Returns

  • Over 1 Month -7.67%
  • Over 3 Month + 8.13%
  • Over 6 Month + 2.79%
  • Over 1 Year -5.42%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 43.6
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 36,247
  • P/B Ratio
  • 4.9
  • Average True Range
  • 51.05
  • EPS
  • 39.02
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -0.59
  • RSI
  • 44.15
  • MFI
  • 51.13

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,428.70
+ 12 (0.85%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹1,450.69
  • 50 Day
  • ₹1,442.08
  • 100 Day
  • ₹1,422.52
  • 200 Day
  • ₹1,410.78

Resistance and Support

1418.6 Pivot Speed
  • R3 1,464.90
  • R2 1,450.10
  • R1 1,433.40
  • S1 1,401.90
  • S2 1,387.10
  • S3 1,370.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 9,357.41 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 13% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
2025-05-29 Audited Results & Final Dividend
2025-02-13 Quarterly Results
Date Purpose Remarks
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

44.72%
30.52%
6.15%
10.62%
0%
5.88%
2.11%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director & CFO
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,428 As on 09 February, 2026 | 10:39

The Market Cap of Ipca Laboratories is ₹36246.7 Cr As on 09 February, 2026 | 10:39

The P/E ratio of Ipca Laboratories is 43.6 As on 09 February, 2026 | 10:39

The PB ratio of Ipca Laboratories is 4.9 As on 09 February, 2026 | 10:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23